- Home
- GPGI vs TVTX Comparison
GPGI vs TVTX Comparison
Compare GPGI & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPGI | TVTX |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | 977 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.8B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | GPGI | TVTX |
|---|---|---|
| Price | $12.93 | $42.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $40.62 |
| AVG Volume (30 Days) | ★ 3.9M | 2.7M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.07% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $768.10 | $44.76 |
| Revenue Next Year | $126.25 | $35.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.07 | $13.88 |
| 52 Week High | $25.66 | $48.61 |
Technical Indicators
Market Signals| Indicator | GPGI | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.71 | 62.11 |
| Support Level | N/A | $26.97 |
| Resistance Level | $17.22 | $48.61 |
| Average True Range (ATR) | 1.08 | 2.21 |
| MACD | -0.19 | -0.28 |
| Stochastic Oscillator | 15.96 | 36.23 |
Price Performance
Historical ComparisonAbout GPGI GPGI Inc.
GPGI Inc is a diversified holding permanent capital platform designed to acquire, own, and scale high-quality businesses that hold great positions in good industries.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.